Monitor early combination trial data for signs of enhanced efficacy over monotherapy; assess whether responses in MTAPdel RASm tumors validate the dual-inhibition hypothesis. This collaboration de-risks Erasca’s development spend while expanding ERAS-0015’s clinical footprint.
Price Chart
Executive Summary
Erasca has entered into a clinical trial collaboration with Tango Therapeutics to evaluate its pan-RAS molecular glue ERAS-0015 in combination with Tango's PRMT5 inhibitor vopimetostat for treating MTAP-deleted RAS-mutant cancers. Erasca will supply ERAS-0015 at no cost, while Tango will sponsor the Phase 1/2 trial. The partnership targets a high unmet need in pancreatic and NSCLC cancers with a dual-pathway inhibition strategy.
Key Facts
- Erasca and Tango Therapeutics announced a clinical trial collaboration to evaluate ERAS-0015 (Erasca) + vopimetostat (Tango) in MTAP-deleted RAS-mutant pancreatic and NSCLC cancers.
- Tango will sponsor the Phase 1/2 trial; Erasca will supply ERAS-0015 at no cost.
- Each company retains full commercial rights; the agreement is non-exclusive.
- Preclinical data suggest ERAS-0015 has 5x greater RAS inhibition potency and up to 21x higher CypA binding affinity vs. RMC-6236.
- ERAS-0015 showed early clinical responses at 8 mg QD in multiple tumor types with different RAS mutations.
Financial Impact
No direct financial outlay from Erasca; potential long-term value creation if combination shows efficacy
Risk Factors
- Combination may not show synergistic efficacy despite strong preclinical rationale
- Safety concerns could emerge with dual pathway inhibition
- Unconfirmed partial responses in monotherapy may not mature into confirmed responses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250024 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 24, 2026 5w ago | 8-K | $17.60 $15.55 | ▼ −11.65% | ▼ −12.96% | $14.94 (−15.09%) |
Aug 17, 2026 6w ago | 144 | $18.28 $16.16 | ▼ −11.60% | ▼ −10.07% | $14.94 (−18.24%) |
Aug 13, 2026 7w ago | Institutional Cluster | $17.86 $15.88 | ▼ −11.09% | ▼ −9.34% | $14.94 (−16.32%) |
Aug 12, 2026 7w ago | 3 | $17.86 $15.88 | ▼ −11.09% | ▼ −9.34% | $14.94 (−16.32%) |
Aug 11, 2026 7w ago | Press Release | $18.58 $16.03 | ▼ −13.72% | ▼ −11.83% | $14.94 (−19.56%) |
Jul 22, 2026 10w ago | Press Release | $19.51 $18.07 | ▲ +7.38% | ▲ +10.28% | $14.94 (+23.40%) |
Jul 14, 2026 11w ago | 8-K | $21.26 $18.58 | ▼ −12.61% | ▼ −14.95% | $14.94 (−29.70%) |
Jul 14, 2026 11w ago | 424B5 | $21.26 $18.58 | ▼ −12.61% | ▼ −14.95% | $14.94 (−29.70%) |
Jul 14, 2026 11w ago | Press Release | $19.50 $18.31 | ▲ +6.10% | ▲ +8.59% | $14.94 (+23.36%) |
Jul 13, 2026 11w ago | Press Release | $19.50 $18.31 | ▼ −6.10% | ▼ −8.59% | $14.94 (−23.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access